THE WOODLANDS, Texas, April 22 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has licensed to Aventis Pharmaceuticals Inc. (NYSE: AVE - News) non-exclusive rights to its gene targeting technologies for use in Aventis' internal research programs. Financial terms of the agreement were not disclosed.
"We are very pleased to have Aventis join the prestigious group of licensees to our patented gene targeting technologies," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "We believe our agreement with Aventis is further affirmation of the value of our patented gene targeting technologies as an integral resource to validate targets for drug discovery."
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company's gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon's corporate website, www.lexicon-genetics.com . |
